Related Experiment Videos
Pravastatin treatment in combined hyperlipidaemia. Effect on plasma lipoprotein levels and size
S Zambon1, A Cortella, G Sartore
1Department of Internal Medicine, University of Padua, Italy.
Insights
Pravastatin effectively lowers cholesterol and apo B in patients with combined hyperlipidaemia but does not alter LDL particle size. This suggests LDL receptor activity variations do not impact LDL size in this condition.
Area of Science:
- Cardiology
- Lipid Metabolism
- Pharmacology
Background:
- Combined hyperlipidaemia and small, dense LDL particles increase myocardial infarction risk.
- Understanding lipoprotein changes is crucial for cardiovascular disease prevention.
Purpose of the Study:
- To evaluate pravastatin's effect on plasma lipoproteins and LDL size in patients with combined hyperlipidaemia.
- To investigate the relationship between LDL receptor activity and LDL size.
Main Methods:
- Single-blind, randomized, placebo-controlled study.
- 24 patients with combined hyperlipidaemia (12 pravastatin, 12 placebo).
- 16-week treatment period; measurements of plasma lipoproteins and LDL size via gradient gel electrophoresis.
Main Results:
- Pravastatin significantly reduced total cholesterol (-15%), LDL cholesterol (-23%), and apo B (-13%).
- Pravastatin significantly increased apo AI (+6%).
- LDL particle size remained unchanged in the pravastatin group compared to placebo. No adverse effects were reported.
Conclusions:
- Pravastatin is effective in improving lipid profiles in combined hyperlipidaemia.
- LDL size is not influenced by changes in LDL receptor activity in this patient group.
Abstract:
Combined hyperlipidaemia and the presence of small and dense LDL particles in the circulation are associated with an increased risk of myocardial infarction. The effect of pravastatin on plasma lipoproteins and on LDL size has been evaluated in a single-blind, randomised, placebo-controlled study in 24 patients with combined hyperlipidaemia; 12 patients on pravastatin and 12 on placebo. After 16 weeks on pravastatin, plasma total (-15%) and LDL (-23%) cholesterol and apo B (-13%) levels were significantly reduced and apo AI (+6%) had increased. LDL size (measured by gradient gel electrophoresis) had not changed. No adverse effect was observed. The study suggests that, in combined hyperlipidaemia, LDL size is not affected by variation in LDL receptor activity.